Search

Your search keyword '"Farwell, W."' showing total 136 results

Search Constraints

Start Over You searched for: Author "Farwell, W." Remove constraint Author: "Farwell, W."
136 results on '"Farwell, W."'

Search Results

4. Tunable SEU-tolerant latch

5. Longer-term Experience with Nusinersen in Teenagers and Young Adults with Spinal Muscular Atrophy: Phosphorylated Neurofilament Heavy Chain (pNF-H) and Efficacy Results From the CS2-12/SHINE Studies

6. Plasma Phosphorylated Neurofilament Heavy Chain Levels Over Time in Participants With Infantile-and Later-onset SMA: Data from the SHINE Study

8. SMA – THERAPY

9. SMA – THERAPY

10. SMA – THERAPY

11. SMA – THERAPY

12. SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES

14. Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): results from the SHINE study

15. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials

16. Neurofilament as a potential biomarker for spinal muscular atrophy

17. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

18. Nusinersen versus sham control in later-onset spinal muscular atrophy

19. Phosphorylated neurofilament heavy chain (PNF-H) and motor function achievement in nusinersen-treated individuals with spinal muscular atrophy (SMA)

20. Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): Interim results from the phase 2 nurture study

21. Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): Results from the shine study

22. P.352Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): results from the SHINE study

23. P.270Association between plasma phosphorylated neurofilament heavy chain and efficacy endpoints in the nusinersen NURTURE study

24. P.356Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy: interim results from the phase 2 NURTURE study

25. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

26. Nusinersen versus sham control in later-onset spinal muscular atrophy

27. SMA THERAPIES II AND BIOMARKERS

28. SMA THERAPIES I

29. NEW GENES, FUNCTIONS AND BIOMARKERS

31. B.06 Safety and efficacy of nusinersen in infants/children with spinal muscular atrophy (SMA): part 1 of the phase 2 EMBRACE study

32. Nusinersen versus sham control in infantile-onset spinal muscular atrophy

40. Efficacy and safety of nusinersen in infants with spinal muscular atrophy (SMA): Final results from the phase 3 ENDEAR study

41. Interim analysis of the phase 3 CHERISH study evaluating nusinersen in patients with later-onset spinal muscular atrophy (SMA): Primary and descriptive secondary endpoints

42. Interim Efficacy and Safety Results from the Phase 3 ENDEAR Study of Nusinersen in Infants Diagnosed with Spinal Muscular Atrophy (SMA)

46. Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.

49. Clinical Meaningfulness of the Changes in Muscle Performance and Physical Function Associated With Testosterone Administration in Older Men With Mobility Limitation

Catalog

Books, media, physical & digital resources